UK markets open in 2 hours 26 minutes

AbbVie Inc. (0QCV.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
146.95-0.42 (-0.28%)
At close: 07:14PM BST
Full screen
Previous close147.37
Bid0.00 x N/A
Ask0.00 x N/A
Day's range146.93 - 147.40
52-week range146.93 - 147.40
Avg. volumeN/A
Market cap2.191B
Beta (5Y monthly)0.56
PE ratio (TTM)0.21
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

    Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO

  • PR Newswire

    Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

    AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime

  • PR Newswire

    AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

    AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcome